Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Jonjones you are right. It is indeed the philosophy to buy this stock as well. One can wait till more good data comes out while the price is higher.
If one googles "sigma-1 receptors in major depression and anxiety", There are a lot of articles about it.
Institutional ownership increased in Q3 of 2016 and short covered 6%.
Short Interest Coverage: Is Advaxis Incorporated (NASDAQ:ADXS)’s Fuel Running High? Reports Show Less Sellers.
http://www.kentuckypostnews.com/2016/12/30/short-interest-coverage-is-advaxis-incorporated-nasdaqadxss-fuel-running-high-reports-show-less-sellers/
I thought that way last year. Short in the box!
I think it would be reasonable if the placebo is SOC.
The following comes from AVXL website:
Human clinical trials
Anavex completed a Phase 2a trial with ANAVEX 2-73 in November 2016.
Thereafter, the Company plans to initiate a potentially pivotal 6/12-month Phase 2/3 trial with ANAVEX 2-73. This trial is expected to include up to 300 mild-to-moderate Alzheimer’s patients.
Clinical trials are conducted by third-party organizations, not by Anavex directly. Trial participants are selected independently of the company to avoid undue influence.
An educated guess would be SOC.
Why did AVXL presentation in CTAD show that it paid Lily and others consulting fee but Biogen?
Agree. Biogen has terminated two contracts which are all relevant to AVXL pipeline in the past half year. It is most likely Biogen and AVXL will be partners.
One possibility is that US government gives a grant to AVXL and the p2/3 can run in both USA and AUS.
Bio, that is exactly what I am thinking too. AVXL does not want to be in the situation to beg partnership. The 8 m largely enhanced AVXL negotiation power.
Lake, I think the current situation meets your assessment. We are now looking for partners after showing what is in our hand.
So the mystery is solved if it is indeed the stock offer. The strategy AVXL used is probably better for the shareholders since we know that we need money to carry out the trials and can either dilute the stock or indirectly offer partnership. We share the pie with others for partnership or we dilute little bit. I think AVXL probably do both the direct dilute for company operation and partnership for trial cost. I would think a partnership with Biogen is in process.
He did not mention where the fund from for the three trials.
Cash could last for two years.
Powerwalker, Thanks a lot to share the info. To help others to send mails to senators Would you mind to post the whole letter and others can modify and send to their senators?
Thanks,
David
From the info on Biogen to terminate those contracts, I would guess the partner would be more likely with Biogen. Biogen can benefit at least three area: ALZ, MS and most of all Proteostasis Therapeutics=homeostasis. Buyout is most likely!!
Hi Nobrainer it is unaccessable.
Jimmy I guess so.
One thing we can conclude is two are mild Alz patients and four are moderate Alz patients.
Looks like today there are some institute buys.
Agree with you.
Assume that AVXL will put the slides on its website tomorrow.
It is 5%. Avxl yesterday rose 13%.
As far as I know AVXL does not make the removal of protein as an indicator.
It looks like the abstracts are unavailable at this time.
Does anyone find the abstracts from both avxl and biogen?
Agree. It is a different market. As I stated before, it is like the car market. One can have conventional market for normal income families while there is also a luxury market for special/high income families. However if one compares the price tag between Neo and CAR-T I would think they are close.
Hi George, I think it should be the mono group. What do you think?
Thanks Ven.
Thanks Neiu.
Hi Xena I think it is like the new Japanese FDA rule. If p2 shows the drug is safe and reasonable efficacy it would be able to market and p3 will continue while the drug is on the market.
Thanks Raja. Here are some items in the act
Broadly speaking, the Cures Act will:
1.Invest $1 billion to address the heroin and prescription opioid epidemic;
2. Invest $1.8 billion into cancer research in order to accelerate discoveries to answers the Vice President Biden’s call for a Cancer Moonshot;
3. Invest $3 billion to build upon the major biomedical research initiatives known as the BRAIN and Precision Medicine Initiatives, which are tackling diseases like Alzheimer’s and creating new research models to find cures and better target treatments;
4. Takes important steps to improve mental health; and
5. Improve the Food and Drug Administration’s drug development process by making sure patients’ voices are part of the decision making process.
The item 3 and 5 may be most relevant to AVXL.
Neiu, do you have chance to look at the presentation from Biogen's P1b results? I meant tomorrow.
Agree. The data can not be available only to the members of CTAD. It has to be PRed.
Biogen will release the abstract tomorrow like AVXL will. It is the results from P1b also the same as AVXL. It would be interesting to compare these two.
Biogen will also present its results at CTAD. The article said that if its Alz drug is successful it will be $20 B worth annually in the context of current best selling drug $14B Humira.
http://www.bizjournals.com/boston/news/2016/12/07/can-biogen-solve-the-alzheimer-s-drug-riddle-we.html
One possibility is that the BP would like to see the results before signing the deal. Dr M can not show the result to BP without PR.
Their drug is to reduce the side effect of donepezil and then one can take 400% more donepezil with less side effect. It was reported that at 26 weeks about 90% of patients had positive effect. Anyone know how long the donepezil effect last?
The author probably messed up ALZ with MS.